VIR

Vir Biotechnology, Inc. (VIR) - Q1 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2025. Vir Biotechnology is a clinical-stage biopharmaceutical company focused on infectious diseases (Chronic Hepatitis Delta/B) and oncology (dual-masked T-cell engagers). The company operates as a single reportable segment and is classified as a large accelerated filer.

Key Financial Metrics

Note: The filing does not provide explicit gross margin or operating margin percentages due to the company's pre-commercial status and net loss position.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased by $53.3 million (94%) primarily due to the expiration of GSK's option to select additional non-influenza targets in Q1 2024, which generated $51.7 million in deferred revenue recognition in the prior year. Collaboration revenue turned negative ($70k) due to cost-sharing adjustments.
• Increased Net Loss: Net loss widened by $55.7 million to $121.0 million. This was driven by a $18.5 million increase in R&D expenses, partially offset by a $12.4 million decrease in SG&A expenses.
• R&D Expense Drivers: R&D increased due to a $30.0 million payment to Alnylam Pharmaceuticals (related to the Restated Alnylam Agreement) and a $17.5 million milestone payment triggered by the first patient enrollment in the Phase 3 ECLIPSE trial for Chronic Hepatitis Delta.
• Investment Gains: The company recognized a $6.4 million unrealized gain on its equity investment in Brii Biosciences, compared to a $5.9 million loss in the prior year.
• Liquidity: Cash and investments decreased by approximately $75.5 million, largely due to the $100 million upfront payment for the Sanofi PRO-XTEN license and the $75 million escrow deposit (classified as restricted cash).

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes existing cash, cash equivalents, and investments ($1.02 billion) are sufficient to fund operations for at least the next 12 months. No shares have been sold under the $300 million At-The-Market (ATM) sales agreement with Cowen as of March 31, 2025.
• Clinical Milestones:
  • Chronic Hepatitis Delta (CHD): First patient enrolled in Phase 3 ECLIPSE trial (March 2025). Plans to initiate ECLIPSE 2.
  • Oncology: Phase 1 data for VIR-5818 (HER2) and VIR-5500 (PSMA) showed promising safety and efficacy. Phase 1 for VIR-5525 (EGFR) expected to begin in Q2 2025.
  • Chronic Hepatitis B (CHB): Functional cure data from MARCH Part B study to be presented at EASL Congress 2025.
• Strategic Agreements:
  • Sanofi: Closed exclusive license for PRO-XTEN masking technology and three TCEs. Paid $100M upfront + $75M escrow.
  • Alnylam: Restated agreement; Alnylam opted out of profit-sharing for elebsiran. Vir Bio assumed full responsibility for development/commercialization in exchange for a $30M payment.
• Risks:
  • Sotrovimab: FDA revoked EUA in Dec 2024; no meaningful future revenue expected from this product.
  • Capital Needs: Significant additional funding may be required to complete development and commercialization. Future equity raises may cause dilution.
  • Regulatory: Success depends on clinical outcomes and regulatory approvals, which are uncertain.

Investor Verification Checklist

• Verify the sustainability of the $1.02 billion cash runway given the $121M quarterly burn rate and upcoming Phase 3 costs.
• Confirm the specific terms and future payment obligations under the Restated Alnylam Agreement and Sanofi license (milestones and royalties).
• Monitor the enrollment progress and interim data readouts for the ECLIPSE Phase 3 trial (CHD) and MARCH Part B study (CHB).
• Assess the impact of the FDA revocation of sotrovimab EUA on future collaboration revenue projections.
• Review the status of the $75 million restricted cash escrowed for the VIR-5525 "first in human" milestone due by 2026.